238 related articles for article (PubMed ID: 10882591)
1. Cross-protection between group A and group B streptococci due to cross-reacting surface proteins.
Stâlhammar-Carlemalm M; Areschoug T; Larsson C; Lindahl G
J Infect Dis; 2000 Jul; 182(1):142-9. PubMed ID: 10882591
[TBL] [Abstract][Full Text] [Related]
2. Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V.
Areschoug T; Stålhammar-Carlemalm M; Larsson C; Lindahl G
Infect Immun; 1999 Dec; 67(12):6350-7. PubMed ID: 10569749
[TBL] [Abstract][Full Text] [Related]
3. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection.
Larsson C; Lindroth M; Nordin P; Stålhammar-Carlemalm M; Lindahl G; Krantz I
Arch Dis Child Fetal Neonatal Ed; 2006 Nov; 91(6):F403-8. PubMed ID: 17056838
[TBL] [Abstract][Full Text] [Related]
4. The streptococcal Blr and Slr proteins define a family of surface proteins with leucine-rich repeats: camouflaging by other surface structures.
Waldemarsson J; Areschoug T; Lindahl G; Johnsson E
J Bacteriol; 2006 Jan; 188(2):378-88. PubMed ID: 16385027
[TBL] [Abstract][Full Text] [Related]
5. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
Bronze MS; Courtney HS; Dale JB
J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
[TBL] [Abstract][Full Text] [Related]
6. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Vaccine; 1999 Feb; 17(5):454-8. PubMed ID: 10073723
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
8. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Infect Immun; 1996 Sep; 64(9):3518-23. PubMed ID: 8751893
[TBL] [Abstract][Full Text] [Related]
9. The R28 protein of Streptococcus pyogenes is related to several group B streptococcal surface proteins, confers protective immunity and promotes binding to human epithelial cells.
Stålhammar-Carlemalm M; Areschoug T; Larsson C; Lindahl G
Mol Microbiol; 1999 Jul; 33(1):208-19. PubMed ID: 10411737
[TBL] [Abstract][Full Text] [Related]
10. Immunological markers of the R4 protein of Streptococcus agalactiae.
Maeland JA; Bevanger L; Lyng RV
Clin Diagn Lab Immunol; 2005 Nov; 12(11):1305-10. PubMed ID: 16275945
[TBL] [Abstract][Full Text] [Related]
11. The detection of streptococcal antigens using monoclonal antibodies.
Harris MC; Polin RA
Clin Lab Med; 1985 Sep; 5(3):545-60. PubMed ID: 3899481
[TBL] [Abstract][Full Text] [Related]
12. BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus.
Santi I; Maione D; Galeotti CL; Grandi G; Telford JL; Soriani M
J Infect Dis; 2009 Aug; 200(4):564-70. PubMed ID: 19586417
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.
Larsson C; Holmgren J; Lindahl G; Bergquist C
Infect Immun; 2004 Feb; 72(2):1184-7. PubMed ID: 14742572
[TBL] [Abstract][Full Text] [Related]
14. Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens.
Meinke AL; Senn BM; Visram Z; Henics TZ; Minh DB; Schüler W; Neubauer C; Gelbmann D; Noiges B; Sinzinger J; Hanner M; Dewasthaly S; Lundberg U; Hordnes K; Masoud H; Sevelda P; von Gabain A; Nagy E
Vaccine; 2010 Oct; 28(43):6997-7008. PubMed ID: 20732466
[TBL] [Abstract][Full Text] [Related]
15. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase.
Santillan DA; Andracki ME; Hunter SK
Am J Obstet Gynecol; 2008 Jan; 198(1):114.e1-6. PubMed ID: 17905172
[TBL] [Abstract][Full Text] [Related]
16. Immune response to superoxide dismutase in group A streptococcal infection.
McMillan DJ; Davies MR; Good MF; Sriprakash KS
FEMS Immunol Med Microbiol; 2004 Apr; 40(3):249-56. PubMed ID: 15039102
[TBL] [Abstract][Full Text] [Related]
17. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.
Cleary PP; Matsuka YV; Huynh T; Lam H; Olmsted SB
Vaccine; 2004 Oct; 22(31-32):4332-41. PubMed ID: 15474726
[TBL] [Abstract][Full Text] [Related]
18. Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections.
Stålhammar-Carlemalm M; Stenberg L; Lindahl G
J Exp Med; 1993 Jun; 177(6):1593-603. PubMed ID: 8496678
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with highly purified cell surface proteins confers protection against experimental group B streptococcal infection.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Adv Exp Med Biol; 1997; 418():851-3. PubMed ID: 9331786
[No Abstract] [Full Text] [Related]
20. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
